Men's hormone care
Testosterone replacement therapy (TRT), with lab-based care
Medical review pending · Last updated
TRT is for men with symptoms of low testosterone that are confirmed by blood tests. If prescribed by a licensed provider, treatment comes with regular monitoring.
Who may be a candidate
Men with consistent symptoms (such as low libido, fatigue, or loss of muscle mass) and repeat early-morning lab results showing low total testosterone. Read about low testosterone symptoms.
What evaluation includes
- Health history, medications, and symptom review
- Two morning total testosterone tests; often LH/FSH, CBC (hematocrit), lipids, and PSA when appropriate
- A video visit with a licensed provider
Treatment options a provider may discuss
FDA-approved testosterone products include injections, topical gels, and other forms. Your provider will discuss which form, if any, fits your needs.
Safety
- Testosterone can raise red blood cell counts (hematocrit), which requires monitoring.
- It can reduce sperm production and fertility.
- It is not for men with breast cancer or known/suspected prostate cancer. Tell your provider about heart disease, sleep apnea, or blood-clot history.
- Topical gels can transfer to women and children through skin contact.
- Testosterone is a controlled substance; misuse can cause serious health effects.
Frequently asked questions
Can testosterone be prescribed through telehealth?
Testosterone is a Schedule III controlled substance. Federal DEA telemedicine flexibilities currently allow prescribing after a video visit without a prior in-person exam through December 31, 2026; rules after that date are pending. State rules also apply. Your provider will follow current requirements.
Do I need blood tests?
Yes. Guidelines call for at least two early-morning total testosterone measurements plus other labs before diagnosis, and periodic labs (including hematocrit) during treatment.
Does TRT affect fertility?
Yes. Testosterone therapy can suppress sperm production. If you may want children, tell your provider; other approaches may be more appropriate.
Sources
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline (2018, PubMed)
- American Urological Association: Testosterone deficiency guideline
- Federal Register: Fourth temporary extension of COVID-19 telemedicine flexibilities for prescribing controlled medications (DEA/HHS, Dec 31, 2025)
Sources are listed for reference and do not imply endorsement. Regulatory status can change; check the date above.
Be first to know when we launch
Care through independent licensed clinicians, starting in select states.